January 11, 2026 (InterContinental San Francisco) — We’re pleased to announce that Dr. Lin Qing, CEO at Lingyi Biotech, will speak at the ACCESS ASIA BD Forum @ JPM 2026.
ACCESS ASIA, hosted by YAFO, builds on the success of ACCESS CHINA, expanding Asia’s leading cross-border biotech platform to connect innovators with global pharma, investors, and strategic partners. Taking place on January 11, 2026, at the InterContinental San Francisco, the forum provides a global stage for Asian biotech companies to showcase their innovation, foster partnerships, and explore new business development opportunities. View more information at: https://biotochina.org/
About Lingyi Biotech
Lingyi Biotech is a clinical-stage biotech company and an innovative leader in the global field of monogenic disease therapy, focusing on critical clinical needs such as metabolic and central nervous system disorders. By leveraging the world’s first regulatable CREATETM gene expression system and an AI-integrated vector design approach, the company is advancing next-generation regulable AAV gene therapy technology (AAV2.0). It has established four core technology platforms covering AAV2.0 vector design, precision-targeted delivery systems, rare disease animal models, and GMP-compliant manufacturing. These platforms enable breakthroughs in key areas, including novel vector development, targeted delivery, and efficient production processes.
About the speaker
Dr. Lin Qing, Founder and CEO of Lingyi Biotech, holds a Ph.D. from Zhejiang University under the mentorship of Academician Chen Yaozhu, with expertise in molecular genetics and gene therapy. Dr. Lin has authored over 20 publications in leading international journals, including Nature and Nature Biotechnology, and has led or contributed to multiple national-level research initiatives. Previously, Dr. Lin served as an independent Principal Investigator and Assistant Professor at the Institute of Genetics of Fudan University and Vanderbilt University School of Medicine, respectively. Dr. Lin also holds appointments as Deputy Director of the National Orphan Drug Committee of the China Biomedical Industry Innovation and Transformation Alliance (CBIITA), Visiting Professor at Zhejiang Science and Technology University and Shenyang Pharmaceutical University.
Dr. Lin brings extensive industrial and entrepreneurial experience, having held senior R&D leadership roles at multinational pharmaceutical companies such as Pfizer, as well as key scientific positions at globally renowned organizations, including WuXi AppTec and Sundia. Over the course of his career, he has contributed to dozens of innovative drug development programs worldwide, successfully advancing more than ten candidates into clinical development. Notably, Dr. Lin played a critical role in the development of three FDA-approved, blockbuster therapies: the IDH1 inhibitor Tibsovo®, an IDH2 inhibitor IDHIFA® with approximately USD half billion in annual sales, and PYRUKYND®, a first-in-class treatment for pyruvate kinase deficiency, addressing major unmet needs in acute myeloid leukemia and hemolytic anemia. In addition, in collaboration with Fudan University, Dr. Lin contributed to the development of the world’s first Tissue Factor (TF)-targeting antibody–drug conjugate (ADC) for pancreatic cancer, with a technology transfer value of RMB 60 million, establishing a landmark precedent for ADC innovation in China.
About ACCESS ASIA BD Forum @ JPM 2026
ACCESS ASIA BD Forum @ JPM is scheduled to be held on January 11, 2026, at the InterContinental San Francisco, alongside the J.P. Morgan Healthcare Conference Week.
This full-day forum will feature keynote speeches, panel discussions, corporate presentations, company showcases, and 1-on-1 partnering meetings connecting Asia’s leading biotech innovators with global pharma, investors, and strategic partners.
Conference Name: ACCESS ASIA BD Forum @ JPM 2026
Date & Venue: January 11, 2026 | InterContinental San Francisco
View more information at: https://biotochina.org/
MORE INFORMATION
Contact Us
Register as an attendee for ACCESS ASIA BD Forum @ JPM:
For more information, please contact:
Wendi Xiang | Wxiang@yafocapital.com
BioToChina.org 